Supernus provides update on SPN-810 phase III clinical trials
Supernus announced the outcome of the planned interim analysis from the first Phase III clinical trial on SPN-810. The Company is developing SPN-810 as a novel treatment for impulsive aggression in patients aged 6 to 12 years who have ADHD. September 18, 2017